Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis

Background The full extent to which childhood pneumococcal conjugate vaccines (PCV) can indirectly reduce illness in unvaccinated populations is not known. We aimed to estimate the magnitude and timing of indirect effects of PCVs on invasive pneumococcal disease. Methods In this systematic review an...

Full description

Bibliographic Details
Main Authors: Shiri, T, Datta, S, Madan, J, Tsertsvadze, A, Royle, P, Keeling, M, McCarthy, N, Petrou, S
Format: Journal article
Published: Elsevier 2017
_version_ 1797072597345632256
author Shiri, T
Datta, S
Madan, J
Tsertsvadze, A
Royle, P
Keeling, M
McCarthy, N
Petrou, S
author_facet Shiri, T
Datta, S
Madan, J
Tsertsvadze, A
Royle, P
Keeling, M
McCarthy, N
Petrou, S
author_sort Shiri, T
collection OXFORD
description Background The full extent to which childhood pneumococcal conjugate vaccines (PCV) can indirectly reduce illness in unvaccinated populations is not known. We aimed to estimate the magnitude and timing of indirect effects of PCVs on invasive pneumococcal disease. Methods In this systematic review and meta-analysis, we searched bibliographic databases for non-randomised quasi-experimental or observational studies reporting invasive pneumococcal disease changes following PCV introduction in unvaccinated populations (studies published Sept 1, 2010, to Jan 6, 2016), updating the previous systematic review of the same topic (studies published Jan 1, 1994, to Sept 30, 2010). Two reviewers extracted summary data by consensus. We used a Bayesian mixed-effects model to account for between-study heterogeneity to estimate temporal indirect effects by pooling of invasive pneumococcal disease changes by serotype and serogroup. Findings Data were extracted from 70 studies included in the previous review and 172 additional studies, covering 27 high-income and seven middle-income countries. The predicted mean times to attaining a 90% reduction in invasive pneumococcal disease were 8.9 years (95% credible interval [CrI] 7.8-10.3) for grouped serotypes contained in the seven-valent PCV (PCV7), and 9.5 years (6.1-16.6) for the grouped six additional serotypes contained in the 13-valent PCV (PCV13) but not in PCV7. Disease due to grouped serotypes contained in the 23-valent pneumococcal polysaccharide vaccine (PPV23) decreased at similar rates per year in adults aged 19-64 years (relative risk [RR] 0.85, 95% CrI 0.75-0.95) and 65 years and older (0.87, 0.84-0.90). However, we noted no changes in either group in invasive pneumococcal disease caused by the additional 11 serotypes covered by PPV23 but not PCV13. Interpretation Population childhood PCV programmes will lead, on average, to substantial protection across the whole population within a decade. This large indirect protection should be considered when assessing vaccination of older age groups. Funding Policy Research Programme of the Department of Health, England.
first_indexed 2024-03-06T23:10:02Z
format Journal article
id oxford-uuid:652267d1-c0e6-49b4-adc7-f57ee81cd3c8
institution University of Oxford
last_indexed 2024-03-06T23:10:02Z
publishDate 2017
publisher Elsevier
record_format dspace
spelling oxford-uuid:652267d1-c0e6-49b4-adc7-f57ee81cd3c82022-03-26T18:23:37ZIndirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:652267d1-c0e6-49b4-adc7-f57ee81cd3c8Symplectic Elements at OxfordElsevier2017Shiri, TDatta, SMadan, JTsertsvadze, ARoyle, PKeeling, MMcCarthy, NPetrou, SBackground The full extent to which childhood pneumococcal conjugate vaccines (PCV) can indirectly reduce illness in unvaccinated populations is not known. We aimed to estimate the magnitude and timing of indirect effects of PCVs on invasive pneumococcal disease. Methods In this systematic review and meta-analysis, we searched bibliographic databases for non-randomised quasi-experimental or observational studies reporting invasive pneumococcal disease changes following PCV introduction in unvaccinated populations (studies published Sept 1, 2010, to Jan 6, 2016), updating the previous systematic review of the same topic (studies published Jan 1, 1994, to Sept 30, 2010). Two reviewers extracted summary data by consensus. We used a Bayesian mixed-effects model to account for between-study heterogeneity to estimate temporal indirect effects by pooling of invasive pneumococcal disease changes by serotype and serogroup. Findings Data were extracted from 70 studies included in the previous review and 172 additional studies, covering 27 high-income and seven middle-income countries. The predicted mean times to attaining a 90% reduction in invasive pneumococcal disease were 8.9 years (95% credible interval [CrI] 7.8-10.3) for grouped serotypes contained in the seven-valent PCV (PCV7), and 9.5 years (6.1-16.6) for the grouped six additional serotypes contained in the 13-valent PCV (PCV13) but not in PCV7. Disease due to grouped serotypes contained in the 23-valent pneumococcal polysaccharide vaccine (PPV23) decreased at similar rates per year in adults aged 19-64 years (relative risk [RR] 0.85, 95% CrI 0.75-0.95) and 65 years and older (0.87, 0.84-0.90). However, we noted no changes in either group in invasive pneumococcal disease caused by the additional 11 serotypes covered by PPV23 but not PCV13. Interpretation Population childhood PCV programmes will lead, on average, to substantial protection across the whole population within a decade. This large indirect protection should be considered when assessing vaccination of older age groups. Funding Policy Research Programme of the Department of Health, England.
spellingShingle Shiri, T
Datta, S
Madan, J
Tsertsvadze, A
Royle, P
Keeling, M
McCarthy, N
Petrou, S
Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis
title Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis
title_full Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis
title_fullStr Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis
title_full_unstemmed Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis
title_short Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis
title_sort indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease a systematic review and meta analysis
work_keys_str_mv AT shirit indirecteffectsofchildhoodpneumococcalconjugatevaccinationoninvasivepneumococcaldiseaseasystematicreviewandmetaanalysis
AT dattas indirecteffectsofchildhoodpneumococcalconjugatevaccinationoninvasivepneumococcaldiseaseasystematicreviewandmetaanalysis
AT madanj indirecteffectsofchildhoodpneumococcalconjugatevaccinationoninvasivepneumococcaldiseaseasystematicreviewandmetaanalysis
AT tsertsvadzea indirecteffectsofchildhoodpneumococcalconjugatevaccinationoninvasivepneumococcaldiseaseasystematicreviewandmetaanalysis
AT roylep indirecteffectsofchildhoodpneumococcalconjugatevaccinationoninvasivepneumococcaldiseaseasystematicreviewandmetaanalysis
AT keelingm indirecteffectsofchildhoodpneumococcalconjugatevaccinationoninvasivepneumococcaldiseaseasystematicreviewandmetaanalysis
AT mccarthyn indirecteffectsofchildhoodpneumococcalconjugatevaccinationoninvasivepneumococcaldiseaseasystematicreviewandmetaanalysis
AT petrous indirecteffectsofchildhoodpneumococcalconjugatevaccinationoninvasivepneumococcaldiseaseasystematicreviewandmetaanalysis